SRZN - Surrozen, Inc./DE

9.8
-1.190   -12.143%

Share volume: 9,597
Last Updated: 04-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$10.99
-1.19
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 12%
Dept financing 14%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-16.52%
1 Month
-16.31%
3 Months
-23.50%
6 Months
-12.26%
1 Year
-12.73%
2 Year
3.18%
Key data
Stock price
$9.80
P/E Ratio 
0.00
DAY RANGE
$9.75 - $10.55
EPS 
-$12.23
52 WEEK RANGE
$6.00 - $18.17
52 WEEK CHANGE
-$13.66
MARKET CAP 
38.406 M
YIELD 
N/A
SHARES OUTSTANDING 
3.206 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.89
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,555
AVERAGE 30 VOLUME 
$13,058
Company detail
CEO: Craig C. Parker
Region: US
Website: https://www.surrozen.com/
Employees: 80
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Surrozen, Inc. discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Recent news
loading